Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esteban S Masuda

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|November 17, 2022
Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical CandidateYan Chen, Hui Li, Rose Yen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2010
Therapeutic targeting of Syk in autoimmune diabetesLucrezia Colonna, Geoffrey Catalano, Claude Chew, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2022
Bicyclic pyrimidine compounds as potent IRAK4 inhibitorsYan Chen, Kin Tso, Thilo J Heckrodt, et al.
The Journal of Allergy and Clinical Immunology|September 5, 2006
Identification of the Syk kinase inhibitor R112 by a human mast cell screenAlexander B Rossi, Ellen Herlaar, Sylvia Braselmann, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|December 25, 2008
Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testingGeorge R Clemens, Raymond E Schroeder, Steven H Magness, et al.
Kidney International|April 20, 2020
Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical modelStephen P McAdoo, Maria Prendecki, Anisha Tanna, et al.
American Journal of Respiratory and Critical Care Medicine|September 30, 2005
Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsivenessShigeki Matsubara, Guiming Li, Katsuyuki Takeda, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2015
Application of cultured human mast cells (CHMC) for the design and structure-activity relationship of IgE-mediated mast cell activation inhibitorsAnkush Argade, Somasekhar Bhamidipati, Hui Li, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GNStephen P McAdoo, John Reynolds, Gurjeet Bhangal, et al.
Chemistry & Biology|October 27, 2007
A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1Tarikere L Gururaja, Stephanie Yung, Rongxian Ding, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|November 17, 2022
Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical CandidateYan Chen, Hui Li, Rose Yen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2010
Therapeutic targeting of Syk in autoimmune diabetesLucrezia Colonna, Geoffrey Catalano, Claude Chew, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2022
Bicyclic pyrimidine compounds as potent IRAK4 inhibitorsYan Chen, Kin Tso, Thilo J Heckrodt, et al.
The Journal of Allergy and Clinical Immunology|September 5, 2006
Identification of the Syk kinase inhibitor R112 by a human mast cell screenAlexander B Rossi, Ellen Herlaar, Sylvia Braselmann, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|December 25, 2008
Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testingGeorge R Clemens, Raymond E Schroeder, Steven H Magness, et al.
Kidney International|April 20, 2020
Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical modelStephen P McAdoo, Maria Prendecki, Anisha Tanna, et al.
American Journal of Respiratory and Critical Care Medicine|September 30, 2005
Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsivenessShigeki Matsubara, Guiming Li, Katsuyuki Takeda, et al.
Bioorganic & Medicinal Chemistry Letters|April 16, 2015
Application of cultured human mast cells (CHMC) for the design and structure-activity relationship of IgE-mediated mast cell activation inhibitorsAnkush Argade, Somasekhar Bhamidipati, Hui Li, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GNStephen P McAdoo, John Reynolds, Gurjeet Bhangal, et al.
Chemistry & Biology|October 27, 2007
A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1Tarikere L Gururaja, Stephanie Yung, Rongxian Ding, et al.
Pageof 4